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Tutkimuksen tausta ja tavoitteet: Sydämen toiminta perustuu elektrokemiallisiin 
muutoksiin sydänlihassolujen kalvojen lävitse. Näitä elektrokemiallisia virtoja kutsutaan 
aktiopotentiaaleiksi. Ne johtavat kalsiumin vapautumiseen solunsisäisistä varastoista, 
kalsiumin sitoutumiseen sarkomeerisiin proteiineihin ja lopulta sydänlihaksen supistumiseen. 
Natrium, kalsium ja kalium ovat tärkeimmät ionit, aktiopotentiaalin kannalta. Nopeat 
natriumvirrat sydänlihassoluissa saavat aikaan solukalvon depolarisaation. 
 
SCN5A on geeni, joka sijaitsee kromosomissa 3p21. Se koodittaa sydänlihassoluissa 
ekspressoituvaa jänniteherkkää Nav1.5-natriumkanavaa, josta natrium virtaa sydänlihassolun 
sytoplasmaan. Potilaat, joilla on SCN5A mutaatio, ilmenee erilaisia vakavia sydämen 
rytmihäiriösairauksia, kuten pitkä QT-oireyhtymä (LQT) ja Brugada syndrooma (BrS). 
 
Tämä tutkimus keskittyy kahteen eri SCN5A mutaatioon: I141V ja R1913C. Tutkimuksen 
tavoitteena oli: 1) Lepotilanteessa SCN5A mutaatiosolujen sykkeen karakterisointi. 2) Tutkia 
SCN5A-mutaatiosolujen lääkevastetta 3) Kuvata ja analysoida visuaalisesti ja Beatview-
ohjelman avulla SCN5A-mutaatiosolut ja kontrollisolut 4) Saada tietoa SCN5A-
mutaatiosoluista, joita ei ole mahdollista analysoida Beatview-ohjelman avulla. 
 
Menetelmät: Kaksi solulinjaa erilaistettiin potilaista, joilla SCN5A-geenin mutaatio ja niitä 
verrattiin terveisiin kontrollisoluihin. Jokaisen linjan solujen käyttäytymistä analysoitiin 
kuvaamalla yksittäisiä, erilaistettuja, sykkiviä sydänlihassoluja. SCN5A-geenin mutaatiota 
kantavilla potilailla esiintyy rytmihäiriöitä rasituksen yhteydessä. Adrenaliinia käytettiin 
ilmentämään tätä in vitro-soluviljelyolosuhteissa. Flekainidin vaikutusta tutkittiin 
sydänsolujen rytmihäiriöihin. Sydänsolujen luokittelu ja analysointi suoritettiin visuallisesti 
ja käyttämällä Beatview-ohjelmaa.  
 
Tutkimustulokset: SCN5A-mutaatiosolujen syketaajuus oli korkeampi kuin kontrollisoluilla. 
Flekainidi laski syketaajuutta jokaisen solulinjan soluilla ja teki tautisoluista tasaisemmin 
sykkiviä. Adrenaliini ei nostanut sykettä oletuksen mukaisesti johtuen todennäköisesti 
korkeasta leposykkeestä. Beatview-ohjelman ja visuaalisen analysoinnin tulokset olivat 
samankaltaisia. 
 
Johtopäätökset: Kuten voitiin olettaa, SCN5A solujen sykkiminen oli epäsäännöllisempää 
kuin kontrollisolujen ja lisäksi niiden syketiheys oli korkeampi. Tautisolujen relaksaatio-aika 
oli myös kontrollisoluja lyhyempi. Flekainidi hidasti SCN5A solujen syketiheyttä ja nosti 
relaksaatioaikaa kaikilla solulinjoilla. 
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Background and aims: Heart function is based on electrochemical changes (action 
potentials) across the cardiomyocyte cell membranes. Action potentials induces the release of 
calcium ions from intracellular stores (sarcoplasmic reticulum), binding of calcium to 
sarcomeric proteins and finally in cardiac muscle contraction. The most important ions, 
which take part in the action potential generation, are sodium, calcium and potassium. The 
rapid flow of sodium ions into the cardiomyocytes causes the depolarization of the cell 
membrane. 
 
SCN5A is the gene located on chromosome 3p21, and it encodes the pore-forming α-subunit 
of the voltage-gated sodium channel Nav1.5. Patients with these mutations in SCN5A gene 
have different inherited arrhythmia syndromes, such as congenital long QT syndrome 
(LQTS) and Brugada syndrome (BrS).  
 
This work will focus on two different SCN5A mutations, I141V and R1913C. It has different 
aims: 1) Baseline beating characterization of cardiomyocytes carrying mutation in SCN5A. 2) 
To study drug responses of cardiomyocytes carrying mutation in SCN5A. 3) Image and 
analyse both visually and using the BeatView software SCN5A mutation –patient specific 
and wildtype (WT) iPSC –derived cardiomyocytes (CMs) 4) To get reliable data of SCN5A 
mutation –patient specific CMs visual inspection was used, if it is impossible to analyze 
signals with BeatView.  
 
Methods: Two of cell lines were derived from patients with mutations in the SCN5A gene 
and they were compared to a control cell line from a healthy individual. Behavior of the cells 
were analyzed using videos of single dissociated beating cardiomyocytes of each cell line. 
Individuals carrying mutations in the SCN5A gene get arrhythmias during exercise. 
Adrenaline was used to replicate this phenomenon in vitro. Flecainide was used to study how 
it effects in good way to arrhythmic symptoms of the CMs. Analyzing and classification of 
CMs were studied both visually and using Beatview software. 
 
Results: Beating frequency of cells with SCN5A mutations was higher than in control cells. 
Flecainide decreased beating frequency of all cell lines and made disease cells more regular. 
Adrenaline did not increase beating frequency in SCN5A cells as assumed most likely due to 
high baseline beating frequency. Similar beating behavior were obtained whether the analysis 
was done by visual analyzing or by using Beatview software.  
 
Conclusions: SCN5A cells beating behaviors were more arrhythmic than control cells and 
beating frequencies was also higher than in control cells. Time cells were relaxed was shorter 
time than in control cells. Flecainide slowed down the beating frequency and increased time 
cells were relaxed in all cell lines.  
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1. Introduction 
	
Since 1995, many mutations in the genes coding for cardiac ion channel subunits or proteins 
interacting with ion channels, were described in patients with a number of inherited 
arrhythmia syndromes (Swan et al. 2014). SCN5A encodes for the α-subunit of the cardiac 
voltage-gated sodium channel Nav1.5 (Butters et al. 2010). The voltage-gated sodium 
channels (Nav) in CM play key roles in cells’ accomplishments to generate and transmit 
electrical signals like action potential (AP). Dysfunction of these channels is typically caused 
by mutations in the SCN5A gene. (Remme, 2013.) 
 
Patients with mutations in SCN5A gene have different inherited arrhythmia syndromes, such 
as congenital long QT syndrome (LQTS) and Brugada syndrome (BrS) (Remme, 2013). In 
the end of 2014, Swan and colleagues reported the new point mutation of SCN5A gene. They 
noticed that this new mutation is connected to the ventricular tachycardia during exercise. 
(Swan et al. 2014.) 
 
Takahashi and Yamanaka published a new way to create pluripotent stem cells by inducing 
mouse embryonic or adult fibroblasts using retroviral vector carrying transcription factors in 
2006 (Takahashi & Yamanaka, 2006). After this remarkable finding, the same has been 
obtained with human somatic cells by several research groups all over the world (Kujala et 
al. 2012; Lan et al. 2013; Sun et al. 2012). Including CMs, human induced pluripotent stem 
cells 
 (hiPSCs) can be differentiated into any cell type of the human body (Mummery et al. 2012).  
hiPSCs can be used as a useful platform for cardiac disease modeling and -drug screening, 
because there are no many human sources of cardiac tissue samples available. However, 
hiPSC derived CMs are structurally and functionally immature. (Keung et al. 2014; 
Robertson et al. 2013.) 
 
In this study, baseline beating characterization and drug responses on SCN5A mutation –
patient specific and wild type (WT) hiPSC –derived CMs were studied. Three cell lines were 
used. Two of these cell lines are derived from patients with mutations I141V or R1913C in 
the SCN5A gene and they will be compared to a control cell line from a healthy individual. 
Behavior of the cells were analyzed using videos of beating cardiomyocytes of each cell line. 
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Beatview software was used to analyzing and visual analysing was used to get reliable data 
of CMs, which are impossible to analyze with BeatView.  
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2. Literature review 
 
2.1 Introduction to cardiac muscle and cardiomyocytes 
 
2.1.1 The structure of heart and cardiac cells 
 
The cardiac muscle, myocardium can be divided into four chambers: left atrium, left 
ventricle, right atrium and right ventricle (Figure 1) (Bjålie et al. 2008; Heikkilä et al. 2008). 
It has four valves: two of atrioventricular (AV) valves, which are between the upper 
chambers (atria) and lower chambers (ventricles) and two valves between chambers and 
arteries (Figure 1) (Bers 2001; Severs, 2000). Heart’s role is to pump oxidized blood to 
peripheral circulation and deoxidized blood to the pulmonary circulation. Valves allow blood 
to flow in only one direction through the heart. The tissue surrounding the cardiac muscle 
cells is rich in collagen fibrils and other components of connective tissue and blood vessels 
and nerves. (Bjålie et al. 2008; Heikkilä et al. 2008.) 
 
In addition to the myocardium, the heart contains also two others tissues, which form the 
heart wall together with myocardium (Bjålie et al. 2008; Heikkilä et al. 2008). The inner 
layer is the endocardium, which is covered by endothelial cells. The outer layer of the heart 
wall, epicardium is surrounded by mesothelial cells. Myocardium’s structure is elongated and 
its contraction capable cells are linked to each other. It is composed of CMs, fibroblasts and 
smooth muscle cells. (Heikkilä et al. 2008.) There are different types of CMs in the 
myocardium: atrial and ventricular CMs, pacemaker cells, in the sinoatrial node (SN) and 
Purkinje fiber cells (Bootman et al. 2006; Dehaan & Eichna, 1961; Moorman & Christoffels, 
2003; Severs, 2000).  Different CMs contribute to structural, biochemical, mechanical and 
electrical properties of the functional heart. Atrial and ventricular CMs form the muscular 
walls of the heart. Pacemaker cells and Purkinje fibers in the conduction system are 
specialized cardiomyocytes that generate and conduct electrical impulses. The SN is 
composed of a group of pacemaker cells, resides in the right atrium generating impulses to 
initiate heart contraction. The atrioventricular node (AVN) is located between the atria and 
ventricles, and it conducts an electrical impulse from the atria to the ventricles. (Bjålie et al. 
2008; Heikkilä et al. 2008.) 
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Figure 1. The heart can be divided into four chambers: left atrium, left ventricle, right atrium 
and right ventricle. It has four valves, two atrioventricular (AV) valves: mitral valve and 
tricuspid valve and two valves between chambers and arteries: aortic valve and pulmonary 
valve (Texas Heart institute). 
 
A typical single ventricular cell is 50-150 µm long and 10-20 µm wide but atrial cells are 
slightly smaller. More than half of the content of the cells is contracting protein material. It is 
organized as hundreds separated filaments, myofibrils, which extend from one end of the cell 
to the other. (Bjålie et al. 2008; Heikkilä et al. 2008.)  
 
Every myofibril consists of molecular structures, sarcomeres that are responsible for the 
contraction of the cell. Sarcomeres are formed by thick and thin myofilaments and Z-discs 
(Figure 2). They are tightly organized to allow strong cell contraction. The length of the 
sarcomere increases from stretched state to extreme contraction from 2.2 µm to 1.6 µm. 
(Bjålie et al. 2008; Heikkilä et al. 2008.) 
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Figure 2. Sarcomere structure. Sarcomeres are formed by thick and thin myofilaments and Z-
discs. Surrounding the Z-line is the region of the I-band and One A-band contains the entire 
length of a single thick filament. (Microscopic Muscle Structure.) 
 
Myosin and actin are the most important sarcomeric proteins of which the filaments are 
formed (Chiu et al. 2010; Clark et al. 2002; Heikkilä et al. 2008). Furthermore, titin (also 
known as connectin) is also important connecting protein in sarcomeres. Every thick 
myofilament consists of hundreds of myosin molecules. (Harris et al. 2011; Heikkilä et al. 
2008.) They are connected to each other by cardiac myosin binding protein C (cMyBP-C). A 
myosin molecule consists of two myosin heavy chains (MHC) and two pairs of different type 
of myosin light chains (MLC1 and MLC2). Actin molecules form thin myofilaments together 
with protein parts including group of troponin and tropomyosin molecules. (Bers, 2001; 
Heikkilä et al. 2008; Tardiff, 2011).) Actin molecule has a special structure for myosin head 
in order to bind myosin and thus to allow the contraction of the sarcomere (Barefield et al. 
2014; Heikkilä et al. 2008). 
 
 
2.1.2 Electrophysiology of cardiomyocytes, cardiac action potential 
 
The function of the heart is based on electrochemical changes across the cardiomyocyte 
membranes. Cardiomyocytes have a remarkable property called electrical excitability. In this, 
depolarization of the membrane above a threshold voltage triggers a spontaneous all-or-none 
response called action potential. This electric activity of the heart can be measured from the 
entire human heart by recording ECG. (Boron & Boulpaep, 2009; Heikkilä et al. 2008.) 
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Electrocardiography (ECG) is one of the most important and most widespread methods to 
explore the electrical activity of the heart using electrodes placed on the patient’s body 
(Boron & Boulpaep, 2009; Heikkilä et al. 2008). In ECG, first wave describes activations of 
the atria and it is named as P wave (Figure 3). The first part of P wave describes the 
previously activated atria and latter part the left atria. Duration of the P wave indicates and 
represents the time that it takes to atrial depolarization. (Kujala et al. 2012; Heikkilä et al. 
2008.) 
 
Activation of pacemaker cells in sinoatrial node (SN), does not show in the ECG, because of 
its resulting electrical current is so small. After this, the cardiac conduction system is 
activated: AV node, His bundle, conduction system and Purkinje fibers. Their activation no 
either shown in ECG. The next wave visible in the ECG is the QRS-complex (Figure 3), 
which arises of ventricular depolarization. This depolarization spreads rapidly through the 
cardiac muscle from epicardium to endocardium, and finally ventricular repolarization 
spreads slowly which can be seen as T wave in ECG (Figure 3). The source of the U wave is 
unknown. (Kujala et al. 2012; Bjålie et al. 2008; Heikkilä et al. 2008.)  
 
In ECG, all of the P-waves and PQ-time (counted from the beginning of the P wave, Q wave 
to start) should be look similar. Shape, length, and direction of QRS-complex is analyzed. Its 
direction can be either positive or negative, depends on the angle of the heart is looked. The 
duration of the QRS-complex is normally less than 120 milliseconds and it is usually 
evaluated based on the width of the QRS-complex. Narrow complex can be a sign of atrial 
arrhythmias, while wide complex may mean ventricular arrhythmias. T-wave should be one 
top and in the same direction with QRS-complex. If there is variation of T-wave’s form, it 
may refer to tendency of arrhythmia. Sometimes U-wave follow T wave but it is smaller and 
same direction with T wave. ST-segment is flat and at the same level with the base line. If the 
ST segment increases, it is often a warning sign of an impending myocardial damage and its 
decrease may be due to chronic ischemia. QT interval announces a slowdown or the 
acceleration of the rhythm depending on whether the time is short or prolonged. (Thaler, 
1999.) 
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Figure 3. Schematic representation of ECG. ECG begins with the P wave caused by atrial 
depolarization. It is followed by the QRS complex, which is caused by ventricular 
depolarization and finally T wave, which represents the ventricular repolarization. The source 
of the U wave is unknown. (Heikkilä et al. 2008.) 
 
Action potential is a transient, regenerative electrical impulse in which the membrane 
potential increases rapidly to a peak that is more positive than the normal, negative resting 
voltage (Bjålie et al. 2008; Heikkilä et al. 2008). The most important ions, which take the 
part in the action potential, are sodium, calcium and potassium. All these ions have their 
corresponding ion channels in the cell membrane. (Bjålie et al. 2008; Boron & Boulpaep, 
2009; Heikkilä et al. 2008.) Electronic impulse is created at the top of the right sinoatrial 
node (SN). In SN, there is cardiac pacemaker (P) cells and they have spontaneous action 
potentials, which based on leaking calcium channels and cause diastolic depolarizations 
(Bjålie et al. 2008; Heikkilä et al. 2008). There are no fast sodium channels in the P cells and 
SN membrane voltage change toward to positive happens via calcium channels. Because of 
the pacemaker role of the SN, cardiomyocytes do not need external stimulation to trigger 
action potentials as neurons do. (Boron & Boulpaep, 2009; Bjålie et al. 2008; Heikkilä et al. 
2008.) 
 
The impulse generated in the same way repeatedly and causes the rhythmically repeated 
electromechanical activation of the heart, which is called the heart rate. Electric activation is 
mediated by specialized conduction system of the heart. The signal goes from the atria to the 
chambers and starts the cardiac muscle contraction. (Bjålie et al. 2008; Heikkilä et al, 2008.) 
Effective action requires mechanical ventricular activation after a suitable delay after 
activation of atria. For this reason, the electric excitation is markedly slower in the 
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atrioventricular node (AV node) than elsewhere in cardiac conduction system. Variability of 
the heart rate and cardiac contraction help the blood flow to adapt to the physiological 
requirements, such as maintaining homeostasis by equalizing the chemical characteristics 
(e.g. pH, and the number of ions) and to transport carbon dioxide to the lungs removing it 
from the body. (Kujala et al. 2012; Bjålie et al. 2008; Heikkilä et al. 2008.) 
 
In axons, Na+ channels are the most important ion channels in initiating action potentials and 
generating fast propagating spikes. However, Ca2+ channels often cause a more sustained 
depolarizing current, which is the reason for the long-life action potentials observed in 
cardiac cells. The action potential causes releasing of calcium ions from intracellular stores 
(sarcoplasmic reticulum) and thus the cardiac muscle contraction. Figure 4 presents how 
cardiac AP can be divided into five phases. (Boron & Boulpaep, 2009; Heikkilä et al. 2008.) 
 
The cell membrane is electrically polarized so that there are negative charges inside the cell 
in relation to the outside of the cell. Between these two sides, a so-called membrane voltage 
potential is normally an average of -90 mV (Figure 4). (Bjålie et al. 2008; Heikkilä et al. 
2008.) When the membrane voltage decreases below -60 mV, the cell membrane will be 
quickly completely depolarized (Phase 0) (Figure 4). After this threshold is exceeded, cell 
membrane passes more Na+ ions and the membrane potential becomes less negative due to 
this ion flow. When it reaches the level of -75 mV, all of the voltage-gated Na+ channels 
open and Na+ ions flow into the cell very quickly. Increased membrane voltage level of 30 
mV leads to closing of the Na+ channels. The higher the diastolic membrane potential, the 
faster is the Phase 0 of the action potential. (Heikkilä et al. 2008.) 
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Figure 4. Cardiac action potential can be divided into five phases: 0) stimulation and rising 
phase, 1) increasing repolarization phase, 2) plateau phase, 3) repolarizing phase and 4) 
resting potential. (McMaster Pathophysiology Review: picture bank). 
 
Local voltage changes in the cell membrane cause opening of the adjacent sodium channels. 
They continue to spread the voltage change along the cell membrane. In the ventricle muscle, 
action potential spreads via gap junctions from one cardiomyocyte to another, eventually 
reaching the last cell. (Boron & Boulpaep, 2009.) 
 
Repolarization (Phase 0) starts when depolarization has reached its peak and Na+ flows stops. 
Repolarization means the recovery of the cell membrane to negative resting potential. When 
Na+ channels are closed, K+ ions stabilize plateau phase (Phase 2) and start to flow outside of 
the cell and extracellular Cl– ions to inside the cell. (Boron & Boulpaep, 2009.) This causes 
opening of voltage-dependent calcium channel (ICa) and Ca2+ ions start to flow into the 
cardiomyocytes from extracellular space (Figure 5). There are two different type of ICa:  
Long-lasting (L)-type (ICa, L) and low-voltage-activated (T)-type (ICa, T). (Bers 2000; Bers 
2001; Bers, 2008.) 
 
When ICa receptors have been activated, intracellular Ca2+ levels increase and it leads to 
activation of ryanodine receptors (RyRs) (Figure 5). This causes Ca2+ flux out of the inner 
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storage, the sarcoplasmic reticulum (SR) and the process is called calcium-induced calcium-
release (CICR) (Figure 5) (Bers, 2002.). Increasing of cytoplasmic Ca2+ concentration make 
Ca2+ ions available to bind to troponin C molecules in the actin filaments. This interaction 
allows actin and myosin binding together and thereby the contraction of the whole 
sarcomere. Calcium enters mitochondria via uniporter and is removed by NCX (Figure 5). 
(Heikkilä et al. 2008.) 
 
When the Ca2+ ions are released from the troponin C molecules, the cardiomyocyte relaxes. 
This occurs when the cytoplasmic Ca2+ concentration is decreased by the sarcoplasmic 
reticulum Ca2+ ATPase (SERCA). This pumps Ca2+ ions back to SR and Na+/Ca2+ exchanger 
pushes them out of the cell. This cytoplasmic Ca2+ concentration lowering causes the 
cardiomyocyte relaxation. (Bers 2000; Bers 2001; Bers, 2008.) 
 
When membrane voltage reaches -50 mV level, outflow of the K+ ions increases, 
repolarization speeds up (Phase 3) (Figure 4) and membrane potential returns to -90 mV 
resting level. Finally, ion concentrations of the resting phase return with the sodium-
potassium exchange pump system and calcium pump system using ATP as the energy source. 
(Bjålie et al. 2008; Heikkilä et al, 2008.) 
 
 
 
 
 
		 11	
 
 
Figure 5. Schematic presentation of calcium transport. Calcium flow into cell via Ica activates 
sarcoplasmic reticulum (SR) and release via the ryanodine receptor (RyR) which leads to 
activation of contraction. SR Ca-ATPase uptakes SR calcium and extrusion via Na/Ca exchange 
(NCX) permits relaxation. Phospholamban (PLB) regulates the activity of SR Ca-ATPase. In 
cytoplasm, free calcium binds to troponin C (TN) on the thin filaments and permits the 
myofibrillar contraction. Calcium enters mitochondria via uniporter and is removed by NCX. 
Calcium in mitochondria activates ATP production. Na-K ATPase and Na/H exchanger 
contribute to the ion balance and potential of the cell. Protons (H+) are pumped out of 
mitochondria by the cytochrome (Cyto). (Bers, 2008.) 
 
 
2.2 SCN5A gene and Nav channels 
 
SCN5A encodes for the α-subunit of the cardiac voltage-gated sodium channel Nav1.5 
(Butters et al. 2010).  These channels control the flow of Na+ ions into cells that initiates the 
depolarizing Phase 0 of the cardiac action potential (Liu et al. 2014). The voltage-gated 
sodium channels (Nav) in CM play key roles in cells’ accomplishments to generate and 
transmit electrical signals like AP (Remme, 2013).  
 
The biophysical properties of the Nav are complex (Liu et al. 2014). Dysfunction of these 
channels is typically caused by mutations in the SCN5A gene. It is located in the chromosome 
3p21 and encodes the major cardiac sodium channel Nav1.5. (Remme, 2013.) The Nav1.5 
channel a subunit forms the ion-conducting pore and changes structural conformation of the 
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channel according to membrane potential. This process is called voltage-depend gating. (Liu 
et al. 2014.) 
 
Nav channels are monomers with four repetitive transmembrane domains (DI-DIV), 
containing six transmembrane (TM) segments (S1-S6) (Amarouch et al. 2014; Chen-Izu et al. 
2015). The first four TM segments (S1-S4) include the voltage-sensing domain (VSD) and 
last two TM segments (S5 and S6) form the pore of the channel when assembled in a 
tetrameric configuration. The α subunit has an intracellular N-terminus and C-terminus and 
four homologous domains (I-IV). (Boron & Boulpaep, 2009.) Furthermore, α subunit 
interacts also with four single b subunits (b1-4) and they play a role in modulating channel 
gating or channel expression. The α and b subunits form a macromolecular complex with 
other proteins and that modulates channel expression and function (Figure 6). (Liu et al. 
2014.) 
 
Since 1995, many mutations in the genes coding for cardiac ion channel subunits or proteins 
interacting with ion channels, were described in patients with a number of inherited 
arrhythmia syndromes (Swan et al. 2014). These syndromes include congenital long QT 
syndrome (LQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular 
tachycardia (CPVT) and progressive cardiac conduction defect disease (CCD), (Swan et al. 
2014; Obeyesekere et al. 2015). There have been also cases describing not the only one of 
these diseases, but combined phenotypes such BrS+CCD or BrS+LQTS (Obeyesekere et al. 
2015). 
 
In the end of 2014, Swan and colleagues reported a novel point mutation of SCN5A gene. 
They noticed that this new mutation is connected to the ventricular tachycardia during 
exercise. (Swan et al. 2014.) Also in many other inherited forms of arrhythmic disorders, 
such as LQT, BrS and CPVT, similar symptoms have been reported (Wilde & Brugada, 
2011). This kind of symptoms are life-threatening because ventricular tachycardia causes 
decreasing of blood pressure, losing consciousness and can lead to death without 
resuscitation (Swan et al 2014).  
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Figure 6. Structure of Nav1.5 channel complex, which is part of a macromolecular complex. 
The α subunit, which is Nav1.5 channel, interacts with multiple cellular proteins, including 
accessory proteins such as β subunits, ankyrin, CAV3, MOG1, syntrophin, and cytoskeleton 
at the cell membrane. (Liu et al.2014.)  
 
 
2.3. Genetic cardiac diseases due mutations in SCN5A gene 
 
2.3.1. LQTS 
 
As mentioned before, the QT interval describes the time to beginning of ventricular 
depolarization to the end of its repolarization (Heikkilä et al. 2008). Long-QT syndrome 
(LQTS) is a cardiovascular disorder characterized by an abnormality in cardiac repolarization 
leading to a prolonged QT interval and T wave on the patient’s ECG (Figure 7) (Splawski et 
al. 2000; Hedley et al. 2009). The patients with LQTS are predisposed to get ventricular 
tachyarrhythmias called Torsades de Pointes (TdP) (Kiviaho et al. 2015) and patients with 
these symptoms have increased risk for sudden death (Remme, 2013).  
 
Various subtypes of LQTS are diagnosed with gene mutations in particular genes and there 
are enormous range of mutations in each gene (Kiviaho et al. 2015). Roughly 5–10 % of 
LQTS patients are carriers of a gain-of-function mutation in SCN5A, the gene encoding the a-
subunit of the LQT3 subtype (Malan et al. 2015). Patients with LQTS type 3 (LQT3, 
associated with SCN5A mutations) present arrhythmias predominantly during rest or sleep at 
slow heart rates, and they are often relatively bradycardic LQT3 patients are especially at risk 
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for sudden death compared to other subtypes, and the first clinical symptom diagnosed is 
often cardiac arrest.  
LQT3 patients typically have defects in fast inactivation of the sodium current, allowing for 
sodium channels to re-open, resulting in a continuous (late) inside flow during the AP plateau 
phase. (Remme, 2013.) 
 
In diagnostics, prolongation of the QT interval is estimated corrected for heart rate. It is 
calculated using Bazett's equation. In the ECG, QTc values over 450 ms in males and 460 ms 
in females can be considered as positive for LQTS. When the QT interval is longer than 500 
ms, the risk for arrhythmias increases. (Vijayakumar et al. 2014.) 
 
 
 
Figure 7. Comparison of a normal ECG compared to one with a prolonged QT interval. In 
ECG the interval from the begin of the Q wave to the end of the T wave is lengthened. 
 
 
2.3.2. Brugada syndrome 
	
In the last decade, studies have started to reveal the genetic background of diseases, which 
are characterized by serious ventricular arrhythmias and sudden death. Ten years ago, a new 
syndrome causing sudden cardiac deaths was discovered. (Brugada P & Brugada J, 1992, 
Heikkilä et al. 2008.) The syndrome was characterized in the ECG with a narrow right bundle 
branch block and a bulge of ST-segment in the right-hand side chest connections (V1-V3) 
(Figure 8) (Brugada et al, 2014). The syndrome was named Brugada syndrome, according to 
its discoverer Pedro Brugada (Escárcega et al, 2009). Congenital defect of the ion channel 
was also the cause of Brugada syndrome, where the SCN5A mutations have been shown to 
cause the syndrome. Consequences of the mutation can be seen as disrupted sodium ion 
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channel activity and weakened flow of the sodium ions. The effect is strongest’ in the right 
ventricle, which explains the ECG finding especially in the right sided chest connections. 
Weakened flow of the sodium shortens the action potential and causes potential differences 
during systole in different areas of the heart, and thus exposes to cardiac arrhythmias either 
during sleep or rest. This can lead to sudden death at worst. (Heikkilä et al. 2008.) 
 
 
Figure 8. Typical ST-segment in V1-V3 coupling in Brugada syndrome. This presents typical 
findings of patient’s ECG with Brugada syndrome. Red narrows in V1 and V2 coupling show 
negative T-wave and blue narrow presents a gradually descending ST-segment. (Heikkilä et 
al. 2008.) 
 
 
2.3.3. CPVT type of phenotype 
 
CPVT is characterized by episodic syncope occurring during exercise or acute emotion in 
individuals without structural cardiac abnormalities. These attacks cause ventricular 
fibrillation and can lead to momentary loss of consciousness or cause sudden death. The 
mean age of onset of symptoms (usually a syncopal episode) is at school age. The heart is 
structurally sound and in diagnostic imaging there is anything unusual and resting ECG is 
normal.  If CPVT in untreated, it is highly lethal and sudden death May be the first 
manifestation of the disease. (Swan et al.1999.) 
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2.4. SCN5A mutations 
 
SCN5A gene mutations have been associated with long QT syndrome (LQTS) type 3, 
Brugada syndrome (BrS), sick sinus syndrome, and cardiac conduction disease (CCD) 
(Bennett et al. 1995; Chen et al. 1998; Jiang et al. 1994).  SCN5A-E1784K is the most 
common mutation associated with BrS and LQTS3 (Veltmann et al. 2016). Table 1 presents 
some of the common SCN5A mutations and cardiac phenotypes of them. 
 
Table 1. SCN5A mutations and their phenotypes 
 
 
The R1913C mutation has unknown pathological significance, but it is known that amino 
acid arginine (R) changes to cysteine (C) at position 1913. A heart disorder characterized by 
LQT interval on the ECG and polymorphic ventricular arrhytmias. Mutation has been 
localized on C-terminus. (Uniprot.) Figure 8 shows localization of this mutation in the Nav1.5 
channel. 
 
In the I141V mutation, amino acid isoleucine (I) is substituted to valine (V) at position 141 
(Amarouch et al, 2014). Figure 9 presents localization of this mutation in Nav1.5 channel. 
This mutation of Nav causes several clinical hyper-excitability phenotypes. Channel window 
current increases due to mutation, while action potential simulations suggested that it lowered 
the excitability threshold of cardiac cells. This predisposes to ventricular extrasystole and 
ventricular fibrillation. (Swan et al. 2014.) 
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Figure 9. Opened structure of Nav1.5 channel in the cell membrane (Figure modified from 
Remme, 2013). Location of p.I141V mutation is marked with red circle and p.R1913C 
mutation with blue circle. Nav channel has four identical parts (DI-DIV) and all of these 
consist of six transmembrane segments (S1-S6). There are also four single b subunits, b1-4, 
of which the first one is shown in the Figure. (Boron & Boulpaep, 2009.) 
 
 
2.5. Induced pluripotent stem cells 
 
In the 2007, Shinya Yamanaka showed with his research group that it is possible to 
reprogram a human somatic cell to a pluripotent stem cell. This can be achieved using a 
retroviral vector carrying four transcription factors, which are required for induction of 
pluripotency: Oct-3/4, Sox2, c-Myc and KLF4. These cells, acting like artificial human 
embryonic stem cells (hES) were named induced pluripotent stem cells (iPS cells). Human 
iPS cells (hiPCs) are able to divide indefinitely and to form all cell types of the body, like 
embryonic stem cells. (Takahashi et al. 2007.) 
 
hiPSCs have similar morphology, proliferation, surface antigens, gene expression, epigenetic 
status of pluripotent cell-specific genes, and telomerase activity like ESs have. hiPS cells can 
be prepared also for example from dermal fibroblasts of adult human who has mutation and 
with this method produced cells can be differentiated into the desired functional cells (Figure 
10). Also, they allow development of patient or disease specific cell lines. This offers a great 
tool to study the disease phenotypes, because the original mutation genotype remains in the 
cells in vitro. (Takahashi et al. 2007.) 
 
hiPSCs are very useful to study genetically inherited diseases affecting tissues which are 
difficult to access, such as the heart. Myocardial biopsy has a high risk for the patient. Many 
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cardiovascular and neural diseases have been studied using hiPSCs. These include for 
example Long-QT –syndromes, catecholaminergic polymorphic ventricular tachycardia, 
Alzheimer’s, Huntington’s diseases and Parkinson’s disease. Furthermore, in addition to the 
Yamanaka’s original method using integrating retroviral vectors, reprogramming can also be 
achieved by using non-integrative vectors, synthetic mRNAs and small molecules. With 
these novel techniques, it is possible to avoid insertional mutagenesis and transgene 
reactivation and thus minimize the risk of tumor formation, cancer risk and variability 
between generated cell lines. (Bellin et al. 2012.) 
 
 
Figure 10. Schematic picture presents how adult somatic cells can be reprogrammed into 
human induced pluripotent stem cells (hiPSC) (Bellin et al. 2012). After in vitro 
differentiation, human iPS cells (hiPSCs) can be used for many different applications. a) 
hiPSCs can be used to study disease phenotypes to understand for example the molecular 
causes for arrhythmias in cardiomyocytes or for defects in neurogenic differentiation. b) drug 
screening and discovery is another application for hiPS cells. With hiPSCs, it is possible to 
discover novel candidate drugs and compounds and to identify target pathways. c) hiPS cells 
have important role in cardiac, neural and liver toxicity tests. With these tests, are possible to 
estimate cellular toxic responses. Drug screening and toxicity tests typify human preclinical 
”trials in a tube” together and that enable the introduction of “the patient” in early stages of 
the drug discovery process. (Bellin et al. 2012.) 
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2.6. hiPSC derived cardiomyocytes 
 
The successful differentiation of human embryonic stem cells (hESCs), and more recently, of 
hiPSCs, into functional cardiomyocytes, has opened new opportunities for cardiovascular 
research and therapies (Mummery et al. 2012). hiPSC differentiation is similar to the 
embryonic development (Bellin et al. 2012) and they can be differentiated into any somatic 
cell of the human body, including CM with different reprogramming methods (Mummery et 
al. 2012).  
 
Cardiogenesis, the differentiation of CMs and mesoderm formation is controlled by three 
families of protein growth factors: Bone morphogenetic proteins (BMPs), the wingless/INT 
proteins (WNTs) and the fibroblast growth factors (FGFs). These growth factors and their 
inhibitors are expressed in endoderm and they started the cardiac transcriptional program, 
which leads to proliferation and maturation of CMs. (Mummery et al. 2012.) 
 
Usually, BMP signaling promotes cardiogenesis, as well as FGFs. The function of WNT 
proteins is more complex and the effects to cardiogenesis dependent on the signaling 
pathway. WNT proteins acting via β-catenin/GSK3 inhibit cardiogenesis, while the acting via 
PKC/JNK (Protein kinase C/ c-Jun-N-terminal kinase) pathway promotes cardiogenesis. 
When the mesoderm cells have acquired the necessary signals, the necessary CMs 
differentiation genes are activated in their genome. Then the cells begin to differentiate and 
expresses typical transcription factors of the heart cells. For example, homeodomain 
transcription factor Nkx2-5, the T-box protein Tbx5 are early markers of the cardiac lineage 
that are activated during the formation of the heart fields. They work together with GATA 
transcription factors and serum response factor (SRF) to activate cardiac structural genes, 
such as myosin light and heavy chains, troponins and desmin. (Mummery et al. 2012.) 
 
The possibilities to produce CMs in vitro, helps to study cardiac diseases. Cardiac research 
has been difficult with unsuitable animal models (mostly rodents with extremely high beat 
rates) and limited amounts of biopsies and tissue samples. Stem cell derived CMs offer an 
unlimited amount of research material. There are many different ways to differentiate CMs: 
embryoid body (EB) method; monolayer culture; inductive co-culture and a new feeder-free 
small molecule method. (Mummery et al. 2012; Lian et al. 2013.) 
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In the EB method, hiPSCs are either fully dissociated and cultured on special modelling 
plates or partly dissociated and cultured on standard cell culture plates to control EB 
formation. EBs are able to form all three germ layers (ectoderm, endoderm and mesoderm). 
They develop into spheroids, 3D-structures of aggregated pluripotent stem cells and they 
develop beating CMs spontaneously. hiPSCs are dissociated and plated as monolayers or 
matrix sandwich using Matrigel cell culture plates in monolayer culture method. With 
monolayer method, diffusion of nutrition and growth factors is more controlled and 
reproducible. (Mummery et al. 2012.) 
 
Inductive co-culture method using a mouse visceral endodermal-like (END-2) cells was 
described by Mummery and colleagues in 2003. This method uses their cell-signaling 
properties advance cardiogenesis (Mummery et al. 2003). In this method, hiPSC lines are 
differentiated by culturing them on top of END-2 cells. With the END-2 method, it is 
possible to get spontaneously beating differentiated CMs using quite small amounts of cells. 
(Mummery et al. 2012.) 
 
Small molecular differentiation method is free of growth factors, and it is suitable for all 
existing human pluripotent stem cell lines. In this method, stem cells are differentiated to 
CMs completely defined and known conditions by temporal modulation of regulators of 
canonical WNTs. It is, therefore, a feeder-free method. (Lian et al. 2013.) Using of culture 
media containing unspecified or undisclosed components has limited the development of 
applications for pluripotent cells (Kusuda-Furue et al. 2010). Feeder cells of animal origin 
and other components using in cell culturing contain animal proteins and other molecules, 
that can move to stem cells during culturing (Ojala et al. 2012). Lack of knowledge of their 
responses to specific cues that control self-renewal, differentiation, and lineage selection 
(Kusuda-Furue et al. 2010). Therefore, this method will enable efficient production of human 
cardiomyocytes for development and disease research, drug screening and testing, and 
advancing cardiac cellular therapies (Lian et al. 2013). 
 
Successful reprogramming of fibroblasts into induced cardiomyocyte-like cells (iCMs) 
without going through an intermediate progenitor or stem cell stage in murine and human 
models has been recently reported. This direct cardiac reprogramming is a potential method 
for regenerative medicine in the future and for dissecting the regulatory control of cell fate 
determination. (Srivastava & Yu, 2015.)  
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Moreover, it offers a new way to understand the transcription factor function and to study the 
complex interplay among transcriptional regulators, miRNAs, and epigenetic regulators 
(Sadahiro et al. 2015). Unlike iPSCs, the iCMs quickly exited the cell cycle and did not form 
colonies and it that is why it is faster method (Srivastava & Yu, 2015). 
 
 
2.7. Drugs affecting cardiomyocyte function 
	
Adrenaline is a hormone, neurotransmitter and it is also used as a medicine. One 
physiological stimulus to adrenaline secretion is during exercise. The body's circulatory 
system adrenaline directly affects both the α- and β-receptors via the indirectly through 
homeostatic reflexes. Adrenaline affects to cardiac adrenergic receptors and it leads to: 1) 
heart rate increases (= positive chronotropic effect), due to sinus node cell depolarization 
acceleration 2) atrial and ventricular contractile force increases (= positive inotropic effect); 
characterized by the systole is reduced and the volume increases heart rate, myocardial 
oxygen consumption increases significantly and thus the efficiency of the heart (work 
compared to oxygen consumption) decreases 3) impulse conduction velocity of heart 
increases 4)   spontaneous activity of pacemaker cells in the chambers increase and this may 
lead to ventricular arrhythmias, for example extrasystole, tachycardia, and even fibrillation. 
(Oulu & Tuomisto, 2007.) 
 
Flecainide slows down the fast sodium channels at the level of the atria, chambers, and 
Purkinje fibers. It does not significantly affect the action potential duration. Flecainide slows 
down conduction in the atrioventricular node and in particular bundle of His and Purkinje 
fibers. Flecainide does not affect the action potential duration. It slows conduction in the atria 
and in the atrioventricular node. However, slowing of the atrioventricular conduction affected 
mainly the His-Purkinje track. It extends the high-speed cable lines refractory in the 
atrioventricular node. This explains the effectiveness of flecainide in the treatment of 
supraventricular tachycardia. (Oulu & Tuomisto, 2007.) 
 
Flecainide is used in clinical. In supraventricular tachycardia the recommended starting dose 
is 100 mg per day. A dose increase should be considered only after 4-5 days of treatment. 
The optimal dose is 200 mg per day. The maximum dose is 300 mg per day. In ventricular 
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tachycardia The usual dose is 200 mg per day. A dose increase should be considered only 
after 4-5 days of treatment. (Orion Pharma.) 
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3. Aims 
 
This research project had two aims: At first study baseline beating characterization of 
cardiomyocytes carrying mutation in SCN5A using various methods to understand what kind 
of phenotypes cells have. And then to study drug responses of cardiomyocytes carrying 
mutation in SCN5A with different methods. 
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4. Materials and methods 
 
4.1. Materials 
 
4.1.1 Patient-specific hiPSC lines and culturing 
	
Three cell lines were used in this study. Two of these cell lines were generated of a patient 
with SCN5A gene mutations. UTA.11705.SCN5A cell line was generated of a patient with 
I141V mutation and UTA.13902.SCN5A cell line of a patient with R1913C mutation. These 
two cell lines were compared to third cell line UTA.04602.WT, generated from a healthy 
individual. All hiPSC cell lines had been produced earlier in our research group according to 
the Yamanaka method, using either dermal fibroblasts or blood cells as starting material. In 
this method, four transcription factors are transfected into the cells (Oct4, Sox2, c-myc and 
Klf4). (Takahashi et al. 2007.) The collection of biopsies for generating patient specific 
hiPSC-lines was approved by the ethical committee of Pirkanmaa Hospital District (Aalto-
Setälä R08070) and written informed consent was obtained from all of the patients.  
 
The clinical phenotype of the patients included the following symptoms:  
- I141V had increasing amount of ventricular extra beats during exercise, but no sudden 
cardiac death or unexplained death at young age has been presented in the family. 
- R1913C presented Brugada type of ECG finding and the patient had been resuscitated 
during a marathon run.  Subsequently he received and intracardiac defibrillator.  
 
Human iPSCs characterization included verification of mutations by qPCR, karyotype 
analysis, verification of gene expression by PCR and protein expression by 
immunochemistry. These had been previously performed in our research group. hiPSCs were 
cultured on mouse embryonic fibroblasts (MEFs, 26 000 cells/cm2, Merck Millipore, MA, 
USA). MEF division was stopped by using mitomycin-C. Therefore, they act as feeder cells 
to promote growth of undifferentiated hiPSCs and to keep their pluripotent state in hES-
medium (Table 2). 
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Table 2. Mediums 
hES medium (20% KO-SR DMEM). Pen/Strep = 10 U/ml Penicillin + 10 
U/ml Streptomycin. 
 
Components Quantity 
Knock-Out DMEM (Life Technologies)  ad 100% 
Knock-Out Serum Replacement (KO-SR, Life Technologies) 20% 
Non-essential amino acids (NEAA, Fischer Scientific) 1% 
GlutaMax (Life Technologies)  2 mM 
Penicillin Streptomycin (Pen Strep) (Fischer Scientific) (50 U/ml) 0.25 ml 
2-mercaptoethanol (Life Technologies) 0.1 mM 
Basic fibroblast growth factor (bFGF, R&D Systems)  
 
4 ng/ml 
END-2 medium  
Components      Quantity 
DMEM-F12 (Life Technologies) ad 100% 
FBS (Immunodiagnostic) 7.5% 
NEAA (Fischer Scientific) 1% 
GlutaMax (Life Technologies) 2 mM 
Penicillin Streptomycin (Pen Strep) (Fischer Scientific) (50 U/ml) 0.25 ml 
 
0% KO-SR hES medium 
 
Components  Quantity 
KO-DMEM (Life Technologies) ad 100% 
NEAA (Fischer Scientific) 1% 
GlutaMax (Life Technologies) 2mM 
Penicillin Streptomycin (Pen Strep) (Fischer Scientific) (50 U/ml) 0,25 ml 
2-mercaptoethanol (Life Technologies) 0.1mM 
Ascorbic acid (Sigma Aldrich), added just before use 3mM 
 
10% KO-SR hES –medium 
 
Components  Quantity 
KO-DMEM (Life Technologies)  ad 100% 
KO-SR (Life Technologies) 10%  
NEAA (Fischer Scientific) 1% 
GlutaMax (Life Technologies) (2mM) 2 mM 
Penicillin Streptomycin (Pen Strep) (Fischer Scientific) (50 U/ml) 0.25 ml 
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4.2 Methods  
 
4.2.1 Cardiomyocyte differentiation 
 
CM differentiation was performed using either END-2 co-culture or small molecule 
differentiation method. 
 
4.2.1.1 END-2 co-culture 
 
To induce differentiation of hiPSCs into CMs, they were co-cultured with murine visceral 
endoderm-like (END-2) cells (prof. Mummery, Humbrecht Institute, Utrecht, The 
Netherlands). END-2 –cells were Mitomycin-C (Sigma Aldrich, MO, USA) inactivated (5 
µl/ml, 3 hours), trypsinized (Lonza, Switzerland) and plated on 12-well-plate (Nunc) 175 000 
cells/well in END-2-medium (Table 2). After overnight incubation (at 37°C), END-2 cells 
were attached and then 0% KO-SR hES medium (Table 2) was changed to them an hour 
before plating the hiPSCs. MEF cells were removed and hiPSC colonies were detached by 
scraping. hiPSC colonies were moved on END-2 cells (~30 colonies/well) with minimal 
amount of culture medium. Then cells were co-cultured in 37°C. At days 5, 8, and 12, 0% 
KO-SR hES-medium was changed and at day 14, the medium was changed to 10% KO-SR 
hES –medium (Table 2) and fresh medium was changed for the cells three times a week. 
	  
2-mercaptoethanol (Life Technologies) 0.1 mM 
 
RPMI+B27-medium 
 
Components Quantity 
RPMI (Fischer Scientific) ad 100% 
B27 (Fischer Scientific) 2% 
Penicillin Streptomycin (Pen Strep) (Fischer Scientific) (50 U/ml) 0.25 ml 
 
EB –medium (20% FBS KO-DMEM) 
 
Components Quantity 
KO-DMEM (Life Technologies)  77.5% 
FBS (Immunodiagnostic)  20% 
NEAA (Fischer Scientific)  1% 
Glutamax (Life Technologies)  2 mM 
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4.2.1.2 Small molecule differentiation 
 
Another method, which was used, is the small molecule differentiation method. It is a feeder-
free method and it is suitable for all human pluripotent stem cells. With this method, it is 
possible to get monolayer cell mat. In small molecule differentiation, RPMI/B27 culture 
medium is used (Table 2). B27 is serum-free nutritional supplement. Insulin has been found 
to inhibit CMs differentiation during the first five days, so, during the differentiation B27 
medium is used without insulin and after differentiation, insulin containing maintenance 
medium is used. (Lian et al. 2013.) 
 
Differentiation is started at day -4 by transferring iPS cells from 6-well-plate to 12-well 
plates (Nunc). Old medium was removed and Accutase enzyme was added (1ml/well, 
incubated 8min at 37°C). After this, mTeSR™1 medium (1 ml/well) was added and the cells 
were flushed off the plate bottom and re-plated on 12-well-plate at 500 000-1 000 000 
cells/well in mTeSR™1 medium with ROCK inhibitor. Medium was changed at days -3, -2 
and -1. 
 
At day 0, insulin-free RPMI/B27 medium (Table 2) with CHIR99021 reagent (12 µM/12-
well-plate) was added. CHIR99021 reagent removed exactly 24 hours after it had been added 
and RPMI/B27 insulin-free medium was added in place of it. At day 3 IWP4 reagent (5 
µM/12-well-plate) was added with RPMI/B27 insulin-free medium. Medium was changed at 
days 5. At day 7 and after it, fresh RPMI/B27 insulin-free medium was changed every third 
day. 
 
Cells were monitored with phase-contrast microscopy using a Nikon Eclipse TS100 
microscope with C-4xB/22 ocular and 4x/0.40 Ph1ADL objective (Nikon, Japan, Tokyo). At 
day 15, hiPSC colonies formed spontaneously beating areas in END2 differentiation methods 
and when using small molecule differentiation strong enough beating areas can be found at 
day 12. 
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4.2.2 Dissociation of beating cardiomyocytes 
 
Before the video analysis, cells were dissociated, separated mechanically both growth plate 
and from each other to allow the recording and analysis of the single cells. At day 16 or later, 
beating areas of cell colonies were cut and separated with scalpel. They were collected in 
culture medium (10% KO-SR hES medium, (Table 2) and dissociated (Mummery et al. 
2003). Beating areas were washed with Low-Ca (buffer 1) (Table 3) at RT for 30 minutes. 
After that, they were treated with collagenase A (Roche Diagnostics, Switzerland) (buffer 2) 
at 37 ˚C for 45 minutes to one hour. Cells were incubated in KB medium (buffer 3) (Table 3) 
at RT for one hour (1M glucose was added to buffer 20 µl to 1ml). Aggregates were 
resuspended in EB medium (20% FBS in KO-DMEM) (Table 2) by pipetting up and down 
against the bottom of the dish until clumps broke up. This helps aggregates to break into 
single cell suspension. Single cell suspension was plated to onto the wells of a 4-plate (one 
beating area/well). 
 
After dissociation, the cells were allowed to settle bottom of the culture plate and attached 
into it. After one day, cells were attached and they were allowed to recover 2-3 days before 
video recording so that they are of uniform quality and beating better. EB medium was 
changed one day before video recording to enhance the beating. 
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Table 3. Components of dissociation buffers. Volumes are for making 100 ml of each buffer 
 
 
 
4.2.3 Video recording of the CMs 
 
On the day of use, coverslip (5 mm diameter), containing the dissociated hiPSC-derived 
CMs, was mounted to an RC-25 recording chamber (Warner Instruments Inc.) and an 
inverted Olympus IX71 microscope (Olympus Corporation) with using UApo/340 x20 air 
objective (Olympus Corporation). CMs were continuously perfused with perfusate medium 
(Table 4). pH of the perfusate medium was set to 7.4 with NaOH and preheated to 35-36∘ C 
by an SH-27B inline-heater controlled by a TC-324B unit (all from Warner Instruments Inc., 
Hamden, USA). The perfusion flow was controlled by a gravity driven VC3 8 application 
system (ALA Scientific Instruments Inc., NY, USA).   
 
CMs in the coverslips were perfused before experimental recordings about 10-15 minutes so 
that the cells became accustomed to fluid flow, perfusate medium and changing conditions. A 
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high-speed camera (Imperx model GEV-B1620M-TC000, Imperx, United States, Florida) 
was connected to microscope to record spontaneously beating CMs for 30 seconds using 60 
fps imaging parameters with JAI Control Tool software. Cells to be recorded were selected 
visually. Requirements for selecting a cell were that the beating is strong enough and steady, 
movement is clearly visible and estimated beating frequency is at least close to the 
physiological range. 
 
 
Table 4. Perfusion liquid components of 500 ml liquid 
 
 
 
4.2.3.1 Drug experiments of UTA.04602.WT cell line 
 
Selected beating areas were cut, dissociated and plated on coverslips. Dissociation was done 
7 days before imaging experiments. EB-culture medium (Table 2) was changed just once in 
week, one day before imaging. This cell line’s cells were used 25 and 32 days after 
differentiation to ensure that they are usable and strong enough for video recording. 
 
Data of the control cell line was collected by taking baseline imaging with perfusate medium 
and after it with 10 µM concentrations of flecainide (Figure 10A). To get this concentration, 
100 µl of 5 mM flecainide was dissolved to 50 ml of perfusate medium (Table 2). Adrenaline 
was not used with WT cells because there was already collected old data enough its effects to 
control cells. After baseline imaging, flecainide (10 µM) was flowed 3 minutes before 
recording (Figure 10A). No more than three cells were used from the same coverslip and it 
was washed 5 minutes with perfusate medium after flecainide before next baseline imaging 
of the same coverslip (Figure 10A and 10B). 
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Figure 11. A) An imaging protocol of UTA.04602.WT cell line. B) An imaging protocol of 
UTA.11705.SCN5A and UTA.13902.SCN5A cell lines. 
 
 
4.2.3.2 Drug experiments of UTA.11705.SCN5A and UTA.13902.SCN5A cell lines 
 
In both experiments, beating areas were cut, dissociated and plated on coverslips.  
Dissociation was done 7 days before imaging in both imaging experiments. EB-culture 
medium (Table 2) was changed just once in week, one day before imaging.  Cells of 
UTA.13902.SCN5A cell line were used 22 and 28 days after differentiation. Cells of 
UTA.11705.SCN5A were used 31 and 37 days after differentiation. 
 
Experiments were started by recording baseline video with perfusate medium (Figure 11B). 
After baseline imaging, adrenaline with 1 µM concentration was used 3 minutes before 
imaging (Figure 11B). 10 µM of 5 mM adrenaline was dissolved to 50 ml of perfusate 
medium (Table 4) to get 1 µM concentration. After adrenaline imaging, 10 µM flecainide 
was flowed 3 minutes before recording (Figure 10B). Also with these cell lines, no more than 
three cells were used from the same coverslip and it was washed 5 minutes with perfusate 
medium after flecainide before next baseline imaging of a cell from the same coverslip 
(Figure 11A and 11B).  
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4.2.4 Beating analysis of cardiomyocytes 
 
BeatView software is designed to analyze the contraction behaviour of single cardiomyocytes 
or their clusters (Ahola et al. 2014). It produces cell contraction and relaxation velocities as a 
function of time and calculates a number of cell contractile activity describing indicators. 
BeatView software has been developed as collaboration with Heart Group of University of 
Tampere and Computational Biophysics and Imaging Group of Tampere University of 
Technology. BeatView software versions 1.12 and 1.2 were used in this study.  
 
From the recorded videos, the CMs were analyzed by manually cropping video at first and 
then selecting the cell of interest. After that, the region of interest (ROI) and the focus point 
of the beating movement were defined by eye. ROIs were divided into 8 sectors around the 
beating focus point. From each of these sectors, two sum vectors for velocity were calculated 
by the software (the radial and tangential component), resulting in 16 signals per cell (f12A). 
Beatview software creates 30 seconds raw signals of these sectors (Figure 12B). Three 
representative raw signals were selected for analysis.  
 
The beating analysis were used to get different parameters from all of the videos: the time 
required for contraction, the time the cell remained contracted, the time needed for 
relaxation, possible incomplete relaxation phase and the time the cell remained relaxed 
(Figure 12C) as well as the beating frequency. BeatView software gives averages of 
parameters of these selected three sectors measurements. Version 1.2, which was launched 
during the project, also gives estimations of the regularity of the beating frequency and 
allows the user to flag abnormal or extra beats.  
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Figure 12. A) Selected cell with the analysis parameters shown. The center of beating 
movement (beating focus point) is marked with pink colour. Radial component is marked 
with green arrow and tangential component is marked with orange arrow. Red circle is the 
manually defined region of interest (ROI). B) 30 seconds signal of cell beating. C) Different 
phases of cardiac contraction/relaxation cycle: (1) the time of contraction, (2) the time the 
cell stayed contracted, (3) the time of relaxation, (4) incomplete relaxation and (5) the time 
the cell was relaxed. 
 
 
4.2.5 Visual analysis of cardiomyocytes 
 
Using the BeatView software proved to be impossible with some cases of the SCN5A cells 
because of their beating behaviour. Thus, also visual analysis of the beating was applied. In 
visual analysis, qualitative classification was used by visual inspection to all three cell lines. 
For this, 30 seconds videos were recorded of 33 of UTA.11705.SCN5A, 25 of 
UTA.13902.SCN5A and 26 of UTA.04602.WT cells. Based on the videos, cells were divided 
into six groups: 1) Regular, 2) Arrhythmic, 3) Vibrating, 4) Twisting, 5) Stopped beating, and 
6) Other. 
 
 
4.2.6 Statistical analysis  
 
P values were calculated using non-parametric Mann-Whitney test with MS Excel. 
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5. Results 
 
In this study, SCN5A mutation specific and WT hiPSC –derived CMs were imaged and 
analyzed both visually and using the BeatView software. SCN5A mutation –patient specific 
CMs were compared with WT CMs. Visual analyzing was used to get reliable data of those 
CMs, which were impossible to analyze with BeatView.  
 
5.1 The analysis of the beating behaviour of single cardiomyocytes 
 
5.1.1 Beating frequency 
	
Beating behavior of single CMs was studied by using BeatView software. Beating of 
dissociated CMs was visualized with a microscope and their motion was video-recorded. 
Time required for each phase of beating was analyzed: the contraction, the time the cell 
stayed contracted, the relaxation time, and the time the cell stayed relaxed. The beating 
frequency was also measured and these results are presented in Figure 13. Figure 13A 
presents all cells’ beating frequencies in normal conditions with perfusate medium. In both 
SCN5A cell lines the frequency was significantly higher (p<0.05) than in WT cells 
(n=10/each cell line). Figures 13B-D present all cell line beating frequencies with perfusate 
medium (baseline), adrenaline and flecainide. In all cell lines, flecainide significantly 
decreased (p< 0.05) beating frequency compared to baseline. Adrenaline slightly but 
significantly increased beating frequency of UTA.11705.SCN5A cells (p<0.05), but there was 
no statistically significant change with adrenaline in the beating frequency of 
UTA.13902.SCN5A cells (p>0.05). 
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Figure 13. A) All cell lines’ cells beating frequency with perfusate medium. B) 
UTA.04602.WT control cell lines cells beating frequency after perfusate medium (blue) and 
flecainide (grey). C) UTA.11705.SCN5A cell line beating frequency after perfusate medium 
(blue), adrenaline (orange) and flecainide (grey). D) UTA.13902.SCN5A cell line beating 
frequency after perfusate medium (blue), adrenaline (orange) and flecainide (grey). For all 
panels, beating frequencies are shown as beats per minute (BPM).  
 
 
When comparing the SCN5A CMs to the WT CMs, average beating frequency was higher. 
Average beating frequency of WT cells were measured as 68 BPM and in SCN5A cells 146 
BPM and 120 BPM with perfusate medium (Table 5). In SCN5A cells, adrenaline increased 
beating frequency 14.5 % and 1.2% on the average (Table 5). Flecainide decreased 34.6 % 
beating frequency in WT cells on the average, when in SCN5A cells, it decreased beating 
frequency 20.7 % and 23.5 %.  
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Table 5. Beating frequencies of all cell lines and the percentage changes. 
 
 
 
5.1.2 Beat phase durations of cardiomyocytes 
	
The durations of beat phases (mainly contraction and relaxation) were studied in all of cell 
lines (Table 6, Figure 14). For UTA.04602.WT CMs, adrenaline was not used after perfusate 
medium because it has studied earlier in Heart Group with different concentrations (0.1nM -
10uM) in WT cells. These earlier studies present that adrenaline increased 81 % beating 
frequencies on the average in WT cells with 1uM concentrations (personal communication). 
For WT cells, flecainide was added directly after perfusate medium. For UTA.11705.SCN5A 
and UTA.13902.SCN5A CMs, adrenaline was used after perfusate medium and flecainide was 
used after it. Figure 14 presents results of the video analysis received signals and average 
results of beat phase durations are shown in Table 6. 
 
The sum displacement vectors were obtained from the video recordings, and several time 
parameters for different phases of beating were measured from these signals: (1) the time of 
contraction, (2) the time the cell stayed contracted, (3) the time of relaxation, (4) incomplete 
relaxation and (5) the time the cell was relaxed (Figure 14).  
 
In WT CMs (n=10), average contraction and relaxation duration decreased after the addition 
of 10 µM flecainide versus perfusate medium (Table 6, Figure 14). Flecainide decreased 
contraction duration 5.2% and relaxation duration 4.7% on the average after baseline in WT 
CMs. Average time for the cell to be in a relaxed state increased 9.8% by flecainide and 
average time of total mechanical activity per beat increased 17.1% also by flecainide (Table 
6, Figure 14).  
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Average contraction duration of UTA. 11705.SCN5A CMs (n=10) increased after 1 uM 
adrenaline 3% versus control medium and decreased 8.7% after 10 uM concentrations of 
flecainide (Table 6, Figure 14) versus adrenaline. Average relaxation duration with perfusate 
medium increased 4.7% after adrenaline and decreased 2.1% by flecainide (Table 6, Figure 
14). Average time for the cell to be in a relaxed decreased 8.1% by adrenaline versus used 
perfusate medium and flecainide increased it 11% after adrenaline (Table 6, Figure 14). 
Adrenaline increased time of total mechanical activity per beat 1.7% after perfusate medium. 
After flecainide it increased 19.7% from 235 to 285 ms (Table 6, Figure 14). 
 
Average contraction percentage of UTA.13902.SCN5A CMs (n=10) increased 2% after 1 uM 
adrenaline versus with perfusate medium and decreased 10.7% after 10 uM concentrations of 
flecainide (Table 6, Figure 14) after adrenaline. Average relaxation duration decreased 4.6% 
by adrenaline compared to with perfusate medium and decreased 3% by flecainide versus 
adrenaline (Table 6, Figure 14). Average time for the cell to be in a relaxed increased 3.3% 
by adrenaline versus used perfusate medium and flecainide also increased it 14% compared 
to adrenaline (Table 6, Figure 14). With perfusate medium time of total mechanical activity 
per beat decreased 3.2% from 341ms to 330ms after adrenaline and flecainide did not change 
it versus adrenaline (Table 6, Figure 14). 
 
Table 6. Average durations of beat phases of all cell lines under different conditions. 
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Figure 14. Illustrations of contraction-relaxation phases of all cell lines presented in Table 6. 
Upper graph presents phase durations as percentages of the one whole cardiac cycle and 
lower graph as milliseconds (ms). Different colors indicate different beat phases as shown 
next to the data columns.  
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5.2 Visual analyzing and classification of cardiomyocytes 
 
Using the Beatview software proved to be impossible with some SCN5A cells because they 
could not be analyzed because of different reasons: 1) technical problems (irregular flow rate 
of perfusion), 2) cell’s beating was too weak or the cell stopped beating (phenotypic for 
SCN5A cells), or 3) the beating movement was twisting and thus impossible to analyze using 
the software. Thus, these cells were analyzed by applying qualitative classification by visual 
inspection to all three cell lines. For this, 30 seconds videos were recorded of 33 of 
UTA.11705.SCN5A, 25 of UTA.13902.SCN5A and 26 of UTA.04602.WT cells. Based on the 
videos, cells were divided into six groups: 1) Regular, 2) Twisting, 3) Arrhythmic, 4) 
fibrillation, 5) Stopped beating, and 6) Other (Table 7). Figure 15 presents the results of the 
visual classification of all cell lines. 
 
The group “Regular” included all regularly contracting cells regardless of beating frequency. 
The group “Twisting” consisted of cells whose beating was rather regular but the direction of 
the contraction and relaxation motion was not direct but rather circular or twisting. The group 
“Arrhythmic” contained cells whose beating was clearly irregular. The cells that did not have 
a clear resting phase but were beating quickly and continuously were classified as 
“Fibrillation”. The group “Stopped beating” consisted of cells that stopped beating during the 
video recording because of stress caused by the recording conditions. The group “Other” 
contains cells that for example oscillated because of irregular flow rate of the perfusate, or 
did not fit in the other groups. Figure 15 presents percentages of CMs in the described 
categories for all cell lines. 
 
Table 7. Classification of all cell lines after visual analyzing.  
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Figure 15. Classifications of cardiomyocytes of all cell lines. For some of the cells, 
classification was also possible with Beatview software. Cells were categorized by visual 
inspection and then data of Beatview software was reviewed. Visual inspection and Beatview 
software’s data matched well. Figure 16 presents four different classes of CMs based both 
visual analyzing of the video and the data obtained from the Beatview software: a) Regular b) 
Twisting c) Arrhythmic and d) Fibrillation.  
 
In Figure 16a), the regular beating rhythm and uniform beats are nicely visible. The signal 
can be also denser, but beating is regular. Figure 16b) the twisting movement is shown. The 
signal contains some doubled waves. When this type cell was visually inspected, it seems 
like cell beats upward with twisting movement. In Figure 16c) presents typical features of 
arrhythmic cell. The beats are uniform but the cell is stuck for a while and then continues 
beating again. Figure 16d) presents fibrillating beating where the signal seems like cell does 
not rest at all between two beats. 
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Figure 16. Different classifications based on data of Beatview software a) Regular cell’s 
beating b) Twisting cell’s beating c) Arrhythmic cell’s beating d) Fibrillating cell’s beating 
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6. Discussion 
	
The aim of this study was to study iPS cell lines established from both control individual and 
patients carrying two different types of SCN5A mutations. The iPS cells were differentiated 
into cardiomyocytes and they were studied as in vitro models.  
 
This study presents methods for analyzing CMs beating behavior both visually and with 
special developed software. Analysis is based on video recording of single beating CMs. 
Adrenaline is used to study in vitro arrhythmic symptoms of CMs with SCN5A mutations. 
Flecainide slow down the fast sodium channels in the atrial level, in chambers and in 
Purkinje fibers (Oulu & Tuomisto, 2007). It was used to study how it effects in good way to 
arrhythmic symptoms of the CMs.  
 
In this study, one of the most important thing was to get well working set-up to analysis of 
the beating behavior of single cardiomyocytes. In Heart Group, cell line with SCN5A 
mutation p.141V (UTA.11705.SCN5A) has studied before with similar methods (Tuominen, 
2015). In his study, the problem was that the effects of adrenaline. Adrenaline did not 
increase beating frequencies of CMs. This was most likely due to high baseline beating 
frequency of the cells. There were changes of pH temperature and moisture because well 
plate was moved back and forth between the microscope and the laminar. Medium was used 
to find out if it effects to beating frequencies of CMs.  
 
6.1 Study setup 
 
In this study, the drug effects on the cells were studied using perfusion. To build a reliable 
set-up, the first thing was to get a steady flow. It seemed that flow rate of perfusate effects to 
contrast of the video. If there were shaking or air bubbles during imaging, the Beatview 
software interpreted those as peaks. In those cases, manual editing of the analysis procedure 
was required. Control of the temperature was also very important. 
 
6.2. Beating behaviours of single cardiomyocytes  
 
In this study, CMs with SCN5A mutations were found to be beating more rapidly than WT 
cells. Perfusate medium was used to analyze the baseline beating behavior of the cells with 
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no drugs present. There are no earlier this kind of studies of SCN5A mutation cells’ beating 
frequencies. It is known that patients with SCN5A mutations might have slower heart rate 
than usual and acceleration of the heart rate during exercise may be deficient (Toivonen et al. 
2008). In this study, beating frequencies were almost two times higher in the SCN5A 
mutation carrying cells than in the WT cells. Adrenaline increases beating frequencies of 
individual CMs and especially I141V mutation cell line (UTA.11705.SCN5A) and this 
suitable for clinical picture of arrhythmias during exercise. Concentration (1µM) and 
duration of treatment were selected based on previous experience (personal communication 
in Heart Group).  
 
Earlier studies in our group present that adrenaline works well with different concentrations 
(0.1nM-10 µM) in WT cells. These earlier studies present that adrenaline increased 81 % 
beating frequencies on the average in WT cells with 1uM concentrations (personal 
communication). For that, adrenaline was used to only CMs with SCN5A mutations. It did 
not increase so much beating frequencies as expected when analyzed with Beatview 
software. However, in visual analysis, adrenaline made disease cells more irregular. The 
adrenaline concentration was selected very high in order to see effects, but the higher doses 
did not change beating behaviors of the SCN5A cells. 
 
Adrenaline is secreted during physical exertion. Patients with SCN5A mutations get 
arrhythmic symptoms during physical exercise when the heart rate is increased. This is why 
adrenaline was used to SCN5A cells in this study to see how it effects in vitro. Adrenaline 
effects by binding to adrenergic receptors. (Niensted et al. 2014.) Total adrenergic signaling 
in the heart is activated via both α- and β-adrenergic receptors, which results in stimulation of 
Protein kinase C (PKC) and Protein kinase A (PKA) signaling pathways, respectively (Chen 
et al. 2016). Earlier study presents that ADRA1A as the main α-adrenergic receptor isoform 
in adult ventricular cardiomyocytes, and human fetal fibroblasts, adult heart samples, as well 
as isolated adult ventricular myocytes showed abundant expression of ADRA1. They found 
that expression of ADAR1 mRNA was markedly downregulated during differentiation from 
all hESC and hiPSC lines. (Földes et al. 2014.) 
 
In this earlier study it is also found that hiPSC-CM were in contrast unresponsive to 
phenylephrine, which is a selective α1-adrenergic receptor agonist.  
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Loss of phenylephrine response was independent from the cell line, cell culture conditions, 
reprogramming, and differentiating protocols they were used and was reproduced in different 
laboratories. Their study presented that cardiomyocytes differentiated from hESCs or hiPSCs 
did not measurably express the ADRA1A gene and ADRA1A mRNA was expressed (albeit 
modestly) in undifferentiated hESCs and hiPSCs but disappeared rapidly during 
differentiation to either cardiomyocytes or fibroblasts. (Földes et al. 2014.)  Also β-
Adrenergic signaling is considered to play a key role in regulating Archangels. A modern-day 
study characterized the properties of b-adrenergic signaling during in vitro differentiation and 
maturation of iPSC-CMs and confirmed active inotropic and chronotropic regulation in these 
models (Chen et al. 2016.). This could also be a reason for the lack of adrenergic effect in our 
cells. 
 
These earlier studies support the idea that something might happen to adrenergic receptors 
after differentiation which might explain why adrenaline was not very effective in this study. 
This will inevitably affect the success and validity of studies. It would be crucial to find out 
what happens to adrenergic receptors during differentiation. Earlier studies also present that 
there are huge differences between mutual cell lines and also the age of the cells affected 
how they behave. (Zhu et al. 2014; Keung et al. 2014.) 
 
Flecainide slows down the fast sodium channels in both the atrial level, that the chambers 
and in the Purkinje fibers (Koulu & Tuomisto, 2007). Our aim was to investigate whether 
flecainide would decrease the beating frequency and abolish arrhytmias of 
the SCN5A mutation carrying cells and this is exactly what was observed. Other studies have 
also presented that flecainide can effectively reduce exercise-induced ventricular arrhythmias 
in patients with CPVT, Andersen–Tawil syndrome (ATS) (Khoury et al. 2013; Delannoy et 
al. 2013, Watanabe et al.2009). Earlier study also presents that in carriers 
of SCN5A mutation, p.I141V carriers (in this study UTA.11705.SCN5A) who exhibited 
frequent multiformic premature ventricular complexes (PVCs) during exercise were 
subjected to exercise stress tests received help of flecainide. Flecainide significantly reduced 
the frequency of PVCs during and after exercise in this study. (Amarouch et al. 2016.) As 
well as previous studies that our study talks about beneficial effects of flecainide treatment 
also in SCN5A related arrhythmias. 
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There are not many published studies about R1913C mutation (in this study 
UTA.13902.SCN5A cell line). One patient with R1913C mutation was involved in study, 
which examined the relationship between repolarization abnormality and coved-type ST-
segment elevation with terminal inverted T-wave (type 1 electrocardiogram [ECG]) in 
patients with Brugada syndrome (BrS) (Nagase et al. 2008). One of our patients 
(UTA.13902.SCN5A) was also a carrier of this R1913C mutation and presented Brugada type 
of clinical phenotype. According to our in vitro study, flecainide could reduce arrhythmias in 
this patient. 
 
Our patients carried different mutations in the same SCN5A gene, but had completely 
different clinical symptoms.  The experimental setup used in this this demonstrated increased 
amounts of arrhythmias in CMs derived from both of these individuals, but could not reveal 
any differences in them.  More sophisticated analysis methods e.g. patch clamp are most 
likely needed to examine the precise electrical abnormalities caused by these two mutations.  
 
In this study, flecainide decreased cells’ beating frequency in all cell lines compared to 
adrenaline or control medium in vitro. Flecainide effects were noticed both by visually 
analyzing and by using Beatview software. Mutant cells can be analyzed much easier and 
faster than if patch clamp method is used. This study gives new data of both I141V and 
R1913C mutation. The clinical investigations of the affected patients, as well as the 
molecular and pharmacological characterization of the SCN5A mutation demonstrate that 
flecainide may serve as an effective treatment for the defect in Nav 1.5 that leads to an 
increased sodium window current (Amarouch et al. 2016). Flecainide is already in clinical 
use. 
 
In addition to the presented drugs, the effect of antiepileptic drugs on the SCN5A cells would 
also be interesting to study. For example, rufinamide enhances the inactivation of sodium 
channels and shortens the QT interval (Wheless & Vazquez, 2010).  
	
6.3 Beat phase durations of cardiomyocytes 
 
In addition to beating frequency, durations of different beating phases of CMs were studied 
based on Beatview software data. Previous studies with LQT cells demonstrated that certain 
types of beating disorders can be detected at this level (Kiviaho et al. 2015) Our hypothesis 
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was that flecainide would increase the duration of the relaxation phase in all cell lines and 
adrenaline (was not used with WT cells) would increase the contraction time of SCN5A cells. 
In baseline, SCN5A cells had very short relaxation time compared to WT cells because of 
high beating frequencies. UTA.11705.SCN5A cells had significantly short relaxation time, but 
UTA.13902 cells had similar relaxation time as in control CMs.  
 
As already mentioned, adrenaline did not effect as assumed. It decreased the duration of the 
contraction phase in UTA.11705.SCN5A cell line but increased the relaxation phase duration. 
With UTA.13902.SCN5A cell line it increased a bit contraction phase duration and decreased 
relaxation phase duration. These unexpected effects might be due the above-mentioned study 
findings that adrenaline did not effects well with differentiated CMs because of adrenergic 
receptors.  
 
Flecainide effected as assumed with all cell lines. In the WT cells its effect was the strongest. 
In the UTA.13902.SCN5A cell line it increased relaxation phase duration more than in 
UTA.11705.SCN5A. However, for both drugs (adrenaline and flecainide) have no clear 
change in beat phases were found. It can be said that these may affect the beating more on the 
general level than changing the duration of a specific phase. Certain types of cells (visually 
weak and slow beating) stopped beating during analysis, or beating weakened or otherwise 
becomes such that it could not be analyzed with Beatview. Weak beating, although not 
analyzable by the software, can be an important phenotype. Therefore, this result is a bit 
biased and it needs to repeat a larger cell population. In order to facilitate the analysis of the 
weak beating could use a higher magnification (40X, instead of now used 20X). Weak or 
stopped beating may be caused by the fact that the cells are relatively young. With more 
mature cells, the result may be different (Zhu et al. 2014; Keung et al. 2014). 
 
6.4 Analyzing and classification of cardiomyocytes – arrhythmia analysis 
 
Analyzing and classification of CMs were done both visually and using the Beatview 
software. The aim was to find out similarities and differences between analyzing visually or 
by using the Beatview software. Visual analyzing increased reliability of this study because 
with some SCN5A cells using the Beatview software proved to be impossible because of cell 
weakness or twisting, or problems in the set-up (see chapter 6.1 for details). Visual 
classification allows all beating subtypes to be analyzed.  
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Visual analyzing and classification were made of baseline videos using the perfusate 
medium. In visual analyzing, four matching classes with Beatview software were found: 1) 
Regular, 2) Regular, but twisting 3) Arrhythmic, 4) Fibrillation. Furthermore, two other 
groups were found by visually: 5) Stopped beating, and 6) Other. Similar groups were easy to 
notice by visually.  
 
It was easy to distinguish differences between WT and SCN5A cells. Visually, WT cells were 
stronger and beat more regular compared to SCN5A cells. No arrhythmic beating behavior 
was detected. Notably, for the WT cells the category “Twisting” contained almost half of the 
cells. This might be due the strong beating or the immaturity of the cells. Twisting class was 
created due to software defects and this class may include also some normal cells. On the 
other hands, iPS-CMs are not mature because they are not elongated, but round and so their 
sarcomeric structure is not well organized (Bellin & Mummery, 2016). Cell shape affect 
strongly on how the beating movement looks like, and may cause the movement to appear 
twisting. Furthermore, there is a lot of discussion about cell’s maturity affecting its behavior 
in vitro. One aspect would be assessing the possibility to use the twisting class as an indicator 
to determine how mature cells are. 
 
In both SCN5A cell lines, the cells were smaller in size, they showed more arrhythmias or 
other abnormal beating behavior, and their overall beating appeared weaker than WT cells. 
SCN5A cells even had fibrillation. It is important to notice that the arrhythmic class was 
huge of UTA.11705.SCN5A CMs, from patient with I141V mutation. CMs with R1913C 
mutation (UTA.13902.SCN5A) behaviors more like WT than I141V mutation CMs. This 
finding describes clinical picture because as mentioned before, patients with this mutation 
had increasing amount of ventricular extra beats during exercise.  
	
6.5 Beatview software  
 
In this study, the Beatview software was used to study beating analysis with geometrical 
sectorial cell division and radial/tangential directions. The beating of dissociated stem cell-
derived cardiomyocytes was visualized with a microscope and the motion was video-
recorded (Ahola et al. 2014). 
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This study presents that it is easier to use software if video quality is sufficient. Incorrect 
lighting (too much or too little light) during video-recording makes video unusable. 
Furthermore, cell selection is a very important step. Selected cell should be strong enough, 
but too rigorous selection criteria can lead to miss important characteristic of phenotype like 
weak beating as this study presented. 
 
 As mentioned before, also perfusate flow rate influenced analyzing. If there were bubbles or 
shaking, it could be seen as an additional peak. Due to the update of the software, these extra 
spikes were easy to discard. The goal is to develop the software by following this studies 
challenges, such as the twisting cells, improve their analysis and thus get more exact results. 
 
A major portion of the WT cells appeared regular but presented twisting in their beating 
behavior.  This complicated the analysis using the Beatview software. The software assumes 
to have unidirectional contraction and relaxation phases, which is not true for twisting cells. 
For these cells, the signals showed double peaks which could not always be analyzed 
correctly. Software will be developed and the result of this study shows that this is an 
important point of development, and these findings also to help in this developing process. 
With SCN5A cells, the main problems were that they were beating so quickly and showed 
plenty of arrhythmias. Too dense beating rhythm complicated the analysis as the consecutive 
beats could not be separated from each other. If the software does not recognize all beats 
correctly, the signal cannot be analyzed reliably. For the arrhythmias, the 1.2 version of the 
software enabled better identification of arrhythmias and irregularities of cells. This property 
was developed specifically to meet the needs of this project. 
 
6.6 Study limitations  
	
In this method, it was important in set-up to get heating to be stable because cells react easily 
to even slight changes of temperature. If the temperature increased over 37’C or decreased 
under it, some CMs stopped beating. At high temperature quickly beating motion is often too 
weak to be analyzed without a recording setup of greater resolution power and lowering the 
temperature decreased CMs beating frequencies. (Laurila et al. 2016.) The present study also 
indicated that flowrate effects the temperature and so also beating. If liquid surface increased, 
temperature decreased and vice versa (Laurila et al. 2016). Controlling and awareness of 
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conditions are important things to get reliable results. In this study, was used to create 
reliable conditions for this type of analysis. 
 
This study should continue to next level to Calcium imaging. Calcium (Ca2+) is a universal 
intracellular second messenger. In muscle, Ca2+ is best known for its role in contractile 
activation (Bers, 2008). Ca2+ -imaging using fluorescent indicators is used to record beating 
frequency and diastolic calcium ion levels of cardiomyocytes during the baseline and 
adrenaline perfusion (Penttinen et al. 2015a).   
 
6.7 Future challenges 
	
It is well established that with single cell types, most often CMs, many cardiac diseases can 
be simulated. hiPSC- derived CMs are useful for modelling inherited human cardiac diseases 
since there are many different examples in which these cells phenocopy the pathogenic 
features of the disease. (Karakikes et, al. 2015.) 
 
It is important to remember that the human heart is composed of vascular, smooth muscle 
and epicardial cells in addition to CMs. 3D cardiac tissue structures should be used to mime 
heart functions better and to typify interactions between different cell types may underlie the 
disease. (Bellin & Mummery, 2016.) Additionally, some diseases may benefit from 
developed culturing techniques, because some phenotypes might become evident only under 
optimized conditions (Birke et al. 2015). It has been also expected that complex multicellular 
structures will be necessary to present fully the pathology of the condition (Bellin & 
Mummery, 2016). 
 
It is also estimated that in the future, iPSCs will find increasing usefulness when combined 
with cardiac tissue engineering (Bellin & Mummery, 2016). To mimic better multicellular 
and dynamic conditions of the cardiovascular system, one should also notice not only known 
or unknown genetic reasons but also issues related to ageing and drug-induced cardiac 
damage (Bellin & Mummery, 2016).  
 
It is expected that to model different dynamics that effect blood flow, mechanical stretch and 
the electrical stimulations leads to structurally and functionally mature human myocardium 
(Bellin & Mummery, 2016). Biological and biophysical readouts that allow high throughput, 
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real-time and quantitative measurement of cardiac (patho)physiological status can be built to 
this myocardium. This can enable studying how the human heart reacts to toxic compounds 
and disease, enhance the integrity of the disease models, and refine the predictability of drug 
responses (Bellin & Mummery, 2016). 
 
At the same time, a big promise is a big challenge: disease treatment and prevention can be 
tailored to the individual with hiPSC technology because hiPSCs represent the genetic 
background of the person. The goal is to utilize hiPSC- derived CMs in personalized 
medicine based on their accomplishments to predict patients’ response to administered drugs. 
In the next few years, hiPSC-CMs based studies should be able to find out applying the same 
drug to patients’ hiPSC-CMs, and following-up over time the patients whether the in vitro 
responses matched the final clinical outcome (Bellin & Mummery, 2016). Previous studies in 
our group presents this with genetic ventricular tachycardia (Catecholaminergic polymorphic 
ventricular tachycardia, CPVT) –derived CMs (Penttinen et al. 2015). 
 
It would be an ideal combination if all of parameters including the structural, molecular and 
electrophysiological characteristics associated with CM maturation could be estimated to 
determine how well the hiPSC-derived CMs resemble myocytes of the human adult heart 
(Bellin & Mummery, 2016). It has been estimated that late hiPSC-CMs (>35 days) are at the 
maturity level of the cardiomyocytes of embryos, but they have similar to the dimensions of 
human embryonic CM but remain small compared to adult (Robertson et al. 2013). It is usual 
to test only some of these parameters, especially those that are most important for the disease 
phenotype to be estimated (Bellin & Mummery, 2016). 
 
It would be also important to find out the physiological processes of maturation and ageing 
that the heart naturally experiences from its formation to birth and during the lifespan of a 
human being in vitro conditions (Veerman et al. 2015; Van meer and Mummery, 2016). 
Because the heart contracts many millions time over a lifetime, aging reveals defects in CMs. 
Maturation is not understood fully. It clearly requires environmental factors like hormones, 
exercise and CM growth by hypertrophy. Prolonged culture, metabolic manipulation, tissue 
engineering technologies, electromechanical pacing and other biophysical approaches are 
used to utilize these issues. (Veerman et al. 2015; Van meer and Mummery, 2016.) 
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An important question is how do we recognize in mature CM in a culture dish. The 
structural, molecular and electrophysiological characteristic are ideally combination of 
parameters associated with CM maturation. These parameters should be assessed to 
determine whether hiPSC-CMs resemble myocytes of the human adult heart (Bellin & 
Mummery, 2016; Robertson et al. 2013). It is typical to practice to test only some of these 
parameters, usually only those that are most important for the disease phenotype to be 
assessed.   
 
All aspects of functionality of the cells, including electrophysiology, calcium handling 
properties, patterns and force of contraction, should be measured (Bellin & Mummery, 
2016). It is possible, that in future there will be application of hiPSC-CMs which would 
estimate their maturation and also 2D and 3D settings will become a useful tool for disease 
modelling and drug testing, as well as for testing conditions that may eventually enhance 
maturation. Other variables, which have an effect to the CM growth, such as substrate 
stiffness and specific molecular cues, need to be determined. It is still indistinct whether an 
adult phenotype will ever be completely achieved in vitro (Bellin & Mummery, 2016). 
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7. Conclusions 
 
In this study, baseline beating characterization and drug responses of hiPSC –derived 
cardiomyocytes (CMs) carrying mutation SCN5A were studied with different methods. They 
were compared to wild type (WT) cells from a healthy individual. SCN5A mutation –patient 
specific and WT iPSC –derived CMs were imaged and analysed both visually and using the 
BeatView software.  
 
At baseline the beating behaviors of diseased cells were more arrhythmic than that of control 
cells and beating frequencies was higher than in control cells. This describes well clinical 
picture of how patients suffering from arrhythmias. The time the cells were relaxed was also 
shorter time than in control cells. Flecainide slowed down the beating frequency and 
increased the time cells were relaxed in all cell lines, as expected but adrenaline did not 
increase bf as well we assumed. Visual analysing was needed to use to get more reliable data 
of the CMs, which are impossible to analyze with the BeatView software. 
 
More studies of the functionality, morphology and maturity of hiPSC –derived CMs are 
needed in the future to find out the true potential of hiPSC –applications in cardiac disease 
modeling. Because hiPSCs represent the genetic background of the person, disease treatment 
and prevention can be tailored to the individual with hiPSC technology. Better differentiation 
methods, tissue engineering studies, advanced culturing conditions and more developed 
software is needed to get more mature hiPSC-CMs for cardiac regenerative medicine. 
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